Targeted News Service

DEA: Continuus Pharmaceuticals Seeks Manufacturing Registration for Fentanyl
August 22, 2025

WASHINGTON, Aug. 22 (TNSFR) -- Continuus Pharmaceuticals, Woburn, Massachusetts, has submitted a request to the U.S. Department of Justice Drug Enforcement Administration for registration as a bulk producer of controlled substances. The application, filed on July 14, 2025, is specifically for the manufacturing of Fentanyl, a Schedule II drug.

The company's application specifies that the purpose of this production is for research and development activities exclusively. The regis . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form